1. Search Result
Search Result
Results for "

TPO

" in MedChemExpress (MCE) Product Catalog:

20

Inhibitors & Agonists

1

Fluorescent Dye

2

Biochemical Assay Reagents

1

Inhibitory Antibodies

1

Natural
Products

18

Recombinant Proteins

3

Isotope-Labeled Compounds

2

Antibodies

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-W017894

    Biochemical Assay Reagents Others
    TPO-L is a photoinitiator for the 3D printing of resin that promotes two-photon induced polymerization. The two-photon absorption cross-section spectrum of Lucirin TPO-L shows a maximum of 1.2 GM at 610 nm. Despite its small two-photon absorption cross-section, Lucirin TPO-L exhibits high polymerization quantum yields .
    TPO-L
  • HY-100380

    Thrombopoietin Receptor Cardiovascular Disease
    TPO agonist 1 is a thrombopoietin (TPO) agonist extracted from patent WO2008134338A1, compound TPO mimetic. It would be useful as promoters of thrombopoiesis and megakaryocytopoiesis to treat thrombocytopenia .
    TPO agonist 1
  • HY-13463B
    Avatrombopag hydrochloride
    3 Publications Verification

    AKR-501 hydrochloride; E5501 hydrochloride; YM477 hydrochloride

    Thrombopoietin Receptor Cardiovascular Disease Cancer
    Avatrombopag (AKR-501) hydrochloride is an orally active, nonpeptide thrombopoietin (TPO) receptor agonist (EC50=3.3 nM). Avatrombopag hydrochloride mimics the biological activities of TPO. Avatrombopag hydrochloride increases platelet production by activating the intracellular signaling system, and promotes production of platelets and megakaryocytes from hemopoietic precursor cells. Avatrombopag hydrochloride is a substrate of cytochrome P450 (CYP) 2C9 and CYP3A .
    Avatrombopag hydrochloride
  • HY-13463
    Avatrombopag
    3 Publications Verification

    AKR-501; E5501; YM477

    Thrombopoietin Receptor Inflammation/Immunology Cancer
    Avatrombopag (AKR-501) is an orally active, nonpeptide thrombopoietin (TPO) receptor agonist (EC50=3.3 nM). Avatrombopag mimics the biological activities of TPO. Avatrombopag increases platelet production by activating the intracellular signaling system, and promotes production of platelets and megakaryocytes from hemopoietic precursor cells. Avatrombopag is a substrate of cytochrome P450 (CYP) 2C9 and CYP3A .
    Avatrombopag
  • HY-13463A
    Avatrombopag maleate
    3 Publications Verification

    AKR-501 maleate; E5501 maleate; YM477 maleate

    Thrombopoietin Receptor Inflammation/Immunology
    Avatrombopag maleate (AKR-501) is an orally active, nonpeptide thrombopoietin (TPO) receptor agonist (EC50=3.3 nM). Avatrombopag maleate mimics the biological activities of TPO. Avatrombopag maleate increases platelet production by activating the intracellular signaling system, and promotes production of platelets and megakaryocytes from hemopoietic precursor cells. Avatrombopag maleate is a substrate of cytochrome P450 (CYP) 2C9 and CYP3A .
    Avatrombopag maleate
  • HY-139915

    Glutathione Peroxidase Inflammation/Immunology
    MPO-IN-1 is a potent, orally active, and irreversible indole-containing inhibitor of myeloperoxidase (MPO). MPO-IN-1 has IC50s of 2.6 μM and 5.3 μM for MPO and thyroid peroxidase (TPO), respectively. MPO-IN-1 inhibits MPO activity in an acute mouse model of inflammation .
    MPO-IN-1
  • HY-19883
    Lusutrombopag
    2 Publications Verification

    S-888711

    Thrombopoietin Receptor Inflammation/Immunology
    Lusutrombopag is an orally bioavailable thrombopoietin (TPO) receptor agonist, used for treatment of chronic liver disease.
    Lusutrombopag
  • HY-RS14941

    Small Interfering RNA (siRNA) Others

    TPO Human Pre-designed siRNA Set A contains three designed siRNAs for TPO gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    TPO Human Pre-designed siRNA Set A
    TPO Human Pre-designed siRNA Set A
  • HY-13463R

    Thrombopoietin Receptor Inflammation/Immunology Cancer
    Avatrombopag (Standard) is the analytical standard of Avatrombopag. This product is intended for research and analytical applications. Avatrombopag (AKR-501) is an orally active, nonpeptide thrombopoietin (TPO) receptor agonist (EC50=3.3 nM). Avatrombopag mimics the biological activities of TPO. Avatrombopag increases platelet production by activating the intracellular signaling system, and promotes production of platelets and megakaryocytes from hemopoietic precursor cells. Avatrombopag is a substrate of cytochrome P450 (CYP) 2C9 and CYP3A .
    Avatrombopag (Standard)
  • HY-145589

    Hetrombopag; SHR-8735

    Thrombopoietin Receptor Cardiovascular Disease
    Rafutrombopag is a thrombopoietin (TPO) agonist extracted from patent CN113929668 A.
    Rafutrombopag
  • HY-19883S

    S-888711-d13

    Isotope-Labeled Compounds Thrombopoietin Receptor Inflammation/Immunology
    Lusutrombopag-d13 is deuterium labeled Lusutrombopag. Lusutrombopag is an orally bioavailable thrombopoietin (TPO) receptor agonist, used for treatment of chronic liver disease.
    Lusutrombopag-d13
  • HY-153239

    Thrombopoietin Receptor Inflammation/Immunology
    Eltrombopag methyl ester is a derivative of Eltrombopag, which is a thrombopoietin (Tpo) receptor agonist, which can promote platelet production and is used in research related to specific types of thrombocytopenia .
    Eltrombopag methyl ester
  • HY-19883R

    Thrombopoietin Receptor Inflammation/Immunology
    Lusutrombopag (Standard) is the analytical standard of Lusutrombopag. This product is intended for research and analytical applications. Lusutrombopag is an orally bioavailable thrombopoietin (TPO) receptor agonist, used for treatment of chronic liver disease.
    Lusutrombopag (Standard)
  • HY-13463BS

    AKR-501-d8 hydrochloride; E5501-d8 hydrochloride; YM477-d8 hydrochloride

    Isotope-Labeled Compounds Thrombopoietin Receptor Cardiovascular Disease
    Avatrombopag-d8 (hydrochloride) is deuterium labeled Avatrombopag (hydrochloride). Avatrombopag (AKR-501) hydrochloride is an orally active, nonpeptide thrombopoietin (TPO) receptor agonist (EC50=3.3 nM). Avatrombopag hydrochloride mimics the biological activities of TPO. Avatrombopag hydrochloride increases platelet production by activating the intracellular signaling system, and promotes production of platelets and megakaryocytes from hemopoietic precursor cells. Avatrombopag hydrochloride is a substrate of cytochrome P450 (CYP) 2C9 and CYP3A[1][2][3].
    Avatrombopag-d8 hydrochloride
  • HY-148748

    JAK STAT p38 MAPK Others
    Butyzamide is an orally active activator of Mpl, a thrombopoietin (TPO) receptor. Butyzamide increases the phosphorylation level of JAK2, STAT3, STAT5 and MAPK. Butyzamide increases the level of human platelets in mouse xenotransplantation assay .
    Butyzamide
  • HY-112486

    Megakaryocytes/platelets inducing agent

    Cyclin G-associated Kinase (GAK) Cardiovascular Disease
    TA-3166 (Megakaryocytes/platelets inducing agent) is a novel chemically synthesized c-MPL agonist (CMA) and thrombopoietin (TPO) receptor agonist. TA-316 enhances ex vivo platelet generation from human-induced pluripotent stem (iPS) cells .
    TA-316
  • HY-112486G

    Megakaryocytes/platelets inducing agent (GMP)

    Cyclin G-associated Kinase (GAK) Cardiovascular Disease
    TA-316 (GMP) is TA-316 (HY-112486) produced by using GMP guidelines. GMP grade small molecules can be used as auxiliary agents in cell therapy. TA-316 is a c-MPL agonist and a thrombopoietin (TPO) receptor agonist .
    TA-316 (GMP)
  • HY-15306S
    Eltrombopag-13C4
    1 Publications Verification

    SB-497115-13C4

    Thrombopoietin Receptor Bacterial Apoptosis Infection Cardiovascular Disease Cancer
    Eltrombopag- 13C4 (SB-497115- 13C4) is 13 sup>C-labeled Z-Eltrombopag. Z-Eltrombopag is an orally active thrombopoietin-receptor non-peptide agonist with platelet-stimulating activity for the study of chronic immune thrombocytopenia. Eltrombopag also has strong inhibitory effects on multidrug-resistant Staphylococcus aureus (Staphylococcus aureus) and can induce apoptosis (apoptosis) in liver cancer cells .
    Eltrombopag-13C4
  • HY-147691

    Glutathione Peroxidase Potassium Channel Inflammation/Immunology
    MPO-IN-5 (compound 1) is a potent, irreversible MPO (myeloperoxidase) inhibitor. MPO-IN-5 inhibits MPO peroxidation and hERG binding, with IC50 values of 0.22 and 2.8 μM, respectively. MPO-IN-5 shows rapid kinetics of inhibition, with enzyme inactivation rate (kinact/Ki) of 23000 M −1s −1 .
    MPO-IN-5
  • HY-W017113

    Endogenous Metabolite Aryl Hydrocarbon Receptor Metabolic Disease
    2-Mercaptobenzothiazole is an activator of the aryl hydrocarbon receptor (AhR) , inhibiting thyroid hormone synthesis and dopamine beta-hydroxylase activity . 2-Mercaptobenzothiazole promotes bladder cancer cell invasion by altering the conformation of the AhR ligand binding domain (LBD), activating AhR transcription, and upregulating the mRNA and protein expression of target genes CYP1A1 and CYP1B1 . 2-Mercaptobenzothiazole inhibits thyroid peroxidase (TPO) with an IC50 value of 11.5 μM, induces histological changes such as follicular cell hypertrophy in Xenopus laevis tadpoles, delaying metamorphosis . 2-Mercaptobenzothiazole increases chromosomal aberrations and sister chromatid exchanges (SCEs) in Chinese hamster ovary (CHO) cells, and enhances carcinogenicity in F344/N rats . 2-Mercaptobenzothiazole inhibits norepinephrine synthesis in mice and completely blocks the conversion of exogenous dopamine to norepinephrine in rat cardiomyocytes .
    2-Mercaptobenzothiazole

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: